Research and Markets: Drug Patent Challenge Report 2011 Profiles More than 80 Drugs and 60 Companies

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fec846/drug_patent_challe) has announced the addition of the "Drug Patent Challenge Report 2011" report to their offering.

This report profiles the companies which have gained marketing exclusivity from the FDA for successfully challenging drug patents.

The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drugs patents.

  • Using data on drugs approved from 2000 to 2009, this report provides complete lists of: A list of the companies with the most successful patent challenges
  • A list of all the drugs for which each firm successfully challenged a patent
  • A list of all the companies that have received FDA approval for each listed drug
  • Report Highlights: More than 60 companies profiled
  • More than 80 drugs profiled

The information is further broken down in the following ways:

Patent Challenger List A list of companies that have successfully challenged patents, in order from most challenges to least. Companies may be listed under multiple names with different spellings.

Details by Patent Challenger A list of the generic drugs for which each applicant successfully challenged a patent, sorted alphabetically by company name. Companies may be listed under multiple names with different spellings.

Details by Drug A list of the companies that have been granted FDA approval to sell each drug. The names of companies which successfully challenged patents are indicated in boldface and further marked with a *.

The following terms are used in this report:

Applicant The firm holding legal responsibility for the new drug application.

Trade Name The trade name of the product as shown on the labeling.

Generic Name / Ingredient The active ingredient(s) for the product. Multiple ingredients are in alphabetical order separated by a semicolon.

New Drug Application (NDA) Number The FDA-assigned number to the application.

Approval Date The date the product was approved as stated in the FDA approval letter to the applicant.

Reference Listed Drug (RLD) The pioneer or innovator version of the drug. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference.

Some of the Topics Covered:

  • Introduction
  • Patent Challenger List
  • Details by Patent Challenger
  • AAIPHARMA LLC
  • ACTAVIS TOTOWA
  • ALPHARMA US PHARMS
  • BARR
  • BAUSCH AND LOMB
  • BRECKENRIDGE PHARM
  • COBALT
  • GLENMARK PHARMS INC
  • HOSPIRA
  • IMPAX LABS
  • MUTUAL PHARM
  • MYLAN
  • NYCOMED US
  • OHM LABS
  • ORCHID HLTHCARE
  • PAR PHARM
  • PERRIGO
  • ROXANE
  • SAGENT STRIDES
  • SANDOZ
  • SICOR PHARMS
  • SUN PHARM INDS
  • TARO
  • TEVA
  • WATSON LABS FLORIDA
  • WYETH CONS
  • Details by Drug

For more information visit http://www.researchandmarkets.com/research/fec846/drug_patent_challe



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.